Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemoid Reaction | 1 | 2024 | 18 | 0.920 |
Why?
|
| Hematology | 2 | 2023 | 243 | 0.830 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2024 | 251 | 0.800 |
Why?
|
| Referral and Consultation | 4 | 2024 | 3599 | 0.790 |
Why?
|
| Factor Xa | 1 | 2021 | 166 | 0.690 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2020 | 118 | 0.660 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2020 | 123 | 0.640 |
Why?
|
| Neutropenia | 1 | 2024 | 885 | 0.630 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 369 | 0.620 |
Why?
|
| Blood Sedimentation | 1 | 2019 | 235 | 0.600 |
Why?
|
| Purpura | 1 | 2018 | 117 | 0.590 |
Why?
|
| Myeloproliferative Disorders | 1 | 2024 | 611 | 0.590 |
Why?
|
| Internal Medicine | 1 | 2024 | 1051 | 0.540 |
Why?
|
| Eosinophilia | 1 | 2020 | 559 | 0.520 |
Why?
|
| Internship and Residency | 6 | 2022 | 5878 | 0.520 |
Why?
|
| Giant Cell Arteritis | 1 | 2019 | 306 | 0.480 |
Why?
|
| Urate Oxidase | 1 | 2014 | 31 | 0.460 |
Why?
|
| Methemoglobinemia | 1 | 2014 | 44 | 0.460 |
Why?
|
| Inpatients | 3 | 2022 | 2544 | 0.440 |
Why?
|
| Clinical Competence | 6 | 2024 | 4789 | 0.420 |
Why?
|
| Gout Suppressants | 1 | 2014 | 177 | 0.410 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 6520 | 0.380 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 1073 | 0.340 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 1303 | 0.320 |
Why?
|
| Medical Oncology | 2 | 2022 | 2317 | 0.310 |
Why?
|
| Teaching Rounds | 3 | 2022 | 275 | 0.310 |
Why?
|
| Hospitals | 1 | 2021 | 3877 | 0.290 |
Why?
|
| Education, Medical, Graduate | 5 | 2023 | 2371 | 0.280 |
Why?
|
| Hospitalists | 2 | 2021 | 294 | 0.270 |
Why?
|
| Curriculum | 6 | 2022 | 3738 | 0.230 |
Why?
|
| Algorithms | 1 | 2024 | 14018 | 0.220 |
Why?
|
| Diagnosis, Differential | 4 | 2024 | 12966 | 0.210 |
Why?
|
| Burnout, Professional | 3 | 2020 | 703 | 0.210 |
Why?
|
| Pandemics | 2 | 2022 | 8645 | 0.210 |
Why?
|
| Podiatry | 1 | 2022 | 28 | 0.210 |
Why?
|
| Leukocytosis | 1 | 2024 | 251 | 0.210 |
Why?
|
| Stroke | 1 | 2024 | 9712 | 0.190 |
Why?
|
| Vermont | 1 | 2020 | 81 | 0.180 |
Why?
|
| Humans | 38 | 2024 | 760617 | 0.180 |
Why?
|
| Accreditation | 1 | 2023 | 473 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2024 | 1597 | 0.170 |
Why?
|
| Problem Solving | 1 | 2022 | 444 | 0.170 |
Why?
|
| North America | 1 | 2023 | 1273 | 0.170 |
Why?
|
| Family Conflict | 1 | 2019 | 95 | 0.160 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 778 | 0.160 |
Why?
|
| Diabetic Foot | 1 | 2022 | 379 | 0.160 |
Why?
|
| Osteomyelitis | 1 | 2022 | 407 | 0.150 |
Why?
|
| Venous Thromboembolism | 2 | 2022 | 1866 | 0.150 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 1392 | 0.150 |
Why?
|
| Focus Groups | 1 | 2024 | 1409 | 0.150 |
Why?
|
| Physicians | 3 | 2020 | 4583 | 0.150 |
Why?
|
| Kinesics | 1 | 2017 | 13 | 0.140 |
Why?
|
| Communication | 3 | 2022 | 3849 | 0.140 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 350 | 0.140 |
Why?
|
| Nonverbal Communication | 1 | 2017 | 62 | 0.140 |
Why?
|
| Psychological Theory | 1 | 2018 | 175 | 0.140 |
Why?
|
| Teaching | 3 | 2021 | 1169 | 0.130 |
Why?
|
| Rheumatology | 1 | 2022 | 615 | 0.130 |
Why?
|
| Trauma Centers | 1 | 2021 | 936 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2015 | 571 | 0.120 |
Why?
|
| Aged | 9 | 2024 | 169042 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2019 | 1526 | 0.110 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 6340 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2024 | 2909 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2018 | 636 | 0.110 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 645 | 0.110 |
Why?
|
| Patient Care | 1 | 2019 | 621 | 0.110 |
Why?
|
| Mutagenesis, Insertional | 1 | 2016 | 656 | 0.110 |
Why?
|
| Heparin | 1 | 2020 | 1632 | 0.110 |
Why?
|
| Medicine | 1 | 2021 | 942 | 0.110 |
Why?
|
| Intelligence | 1 | 2018 | 923 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2024 | 80566 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2019 | 1088 | 0.100 |
Why?
|
| Learning | 2 | 2018 | 1740 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 1580 | 0.090 |
Why?
|
| Neutrophils | 1 | 2024 | 3763 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2015 | 1087 | 0.090 |
Why?
|
| Headache | 1 | 2019 | 1255 | 0.090 |
Why?
|
| Alternative Splicing | 1 | 2015 | 1088 | 0.090 |
Why?
|
| Adult | 7 | 2024 | 220969 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 2574 | 0.080 |
Why?
|
| Quinazolines | 1 | 2016 | 1371 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2014 | 1835 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 1418 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 5672 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 2568 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 14648 | 0.080 |
Why?
|
| Motivation | 1 | 2018 | 2003 | 0.080 |
Why?
|
| Boston | 1 | 2020 | 9313 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 3822 | 0.070 |
Why?
|
| Biopsy | 1 | 2019 | 6762 | 0.070 |
Why?
|
| Palliative Care | 1 | 2022 | 3592 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 13382 | 0.070 |
Why?
|
| Education, Medical | 1 | 2018 | 1724 | 0.070 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 2553 | 0.060 |
Why?
|
| Male | 7 | 2024 | 360358 | 0.060 |
Why?
|
| Students, Medical | 1 | 2018 | 1934 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2015 | 2008 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5835 | 0.060 |
Why?
|
| Female | 8 | 2024 | 392148 | 0.060 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 1115 | 0.060 |
Why?
|
| Licensure, Medical | 1 | 2024 | 71 | 0.050 |
Why?
|
| Middle Aged | 3 | 2024 | 220584 | 0.050 |
Why?
|
| Pyridines | 1 | 2015 | 2874 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7389 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15251 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5332 | 0.050 |
Why?
|
| Faculty, Medical | 2 | 2021 | 1204 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 204 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 26049 | 0.040 |
Why?
|
| United States | 3 | 2024 | 72272 | 0.040 |
Why?
|
| Problem-Based Learning | 1 | 2022 | 356 | 0.040 |
Why?
|
| Jurisprudence | 1 | 2019 | 109 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2015 | 1626 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2024 | 1252 | 0.030 |
Why?
|
| Feedback | 1 | 2020 | 790 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2015 | 2425 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 13635 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 495 | 0.030 |
Why?
|
| Anticoagulants | 2 | 2020 | 4785 | 0.030 |
Why?
|
| Peer Group | 1 | 2020 | 692 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 349 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 905 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 928 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 4512 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 88234 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 709 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 30016 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2015 | 64568 | 0.020 |
Why?
|
| Leadership | 1 | 2020 | 1385 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2020 | 3418 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 6126 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2020 | 3900 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 54360 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3239 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5780 | 0.020 |
Why?
|
| Parents | 1 | 2019 | 3563 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2015 | 8311 | 0.010 |
Why?
|
| Risk Factors | 2 | 2022 | 74115 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2812 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7402 | 0.010 |
Why?
|
| Incidence | 1 | 2020 | 21337 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12719 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 20074 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11116 | 0.010 |
Why?
|
| Genotype | 1 | 2015 | 12978 | 0.010 |
Why?
|
| Genomics | 1 | 2015 | 5822 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 16967 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41457 | 0.010 |
Why?
|
| Prognosis | 1 | 2016 | 29600 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 39063 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 20556 | 0.010 |
Why?
|
Concepts
(152)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(55)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_